SEC Tracker
Get the app

Vir Biotechnology VIR

Vir Biotechnology gets FDA Fast Track for Vir-5500

Form
8-K
Filed
Importance
Routine
  1. FDA granted Fast Track designation to Vir-5500 for late-line mCRPC
  2. Vir-5500 is co-developed with Astellas Pharma
  3. Phase 3 trials expected to start in 2027
  4. Vir-5500 uses PRO-XTEN masking technology

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Vir Biotechnology files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. ImmunityBio IBRX public float $690M, Jun 30, 2025
  2. Anavex Life Sciences AVXL public float $708M, Mar 31, 2025, over 18 months old
  3. Immunome IMNM public float $729M, Jun 30, 2025
  4. Anaptysbio ANAB public float $633M, Dec 31, 2025
  5. Amphastar Pharmaceuticals AMPH public float $633M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.